Anthony Thomas Dren
Consulting Professor in the School of Nursing
Design and execution of drug development clinical research studies.
Current Appointments & Affiliations
- Consulting Professor in the School of Nursing, School of Nursing, Duke University 2003
Contact Information
- Box 3322 Med Ctr, Durham, NC 27710
- Room 3214 Ipe Building, Duke University Sch of Nursing, Durham, NC 27710
-
tony.dren@duke.edu
(919) 668-5107
- Background
-
Education, Training, & Certifications
- Ph.D., University of Michigan, Ann Arbor 1966
-
Previous Appointments & Affiliations
- Consulting Professor in Nursing, School of Nursing, Duke University 1999 - 2003
- Instructor, Temporary in the School of Nursing, School of Nursing, Duke University 1999
- Research
-
Selected Grants
- Clinical Research Management Program for Nurses awarded by Health Resources and Service Administration 2006 - 2009
- Publications & Artistic Works
-
Selected Publications
-
Academic Articles
-
Dren, A. T., and G. H. Turner. “The drug development process: Challenges, changes, and careers. Part I.” Advance for Nurses 2, no. 20 (2000): 20–22.
-
Dren, A. T., and G. H. Turner. “The drug development process: Challenges, changes, and careers. Part II.” Advance for Nurses 2, no. 21 (2000): 18–28.
-
Anderson, G. D., M. K. Yau, B. E. Gidal, S. J. Harris, R. H. Levy, A. A. Lai, K. B. Wolf, W. A. Wargin, and A. T. Dren. “Bidirectional interaction of valproate and lamotrigine in healthy subjects.” Clinical Pharmacology and Therapeutics 60, no. 2 (August 1996): 145–56. https://doi.org/10.1016/s0009-9236(96)90130-7.Full Text
-
Risner, M. E., G. P. Womble, A. T. Dren, and P. K. Manasco. “Long-term clinical trial experience with Lamictal (lamotrigine) treatment of epilepsy.” Epilepsia 36, no. Suppl 4 (1995): 66.
-
Bergen, D., R. Ristanovic, D. Rudd, A. T. Dren, and K. Klein. “Placebo-controlled evaluation of clinical laboratory data and body weight during administration of Lamictal in outpatients with partial seizures.” Epilepsia 35, no. Suppl 8 (1994): 1963.
-
Matsuo, F., D. Bergen, E. Faught, J. A. Messenheimer, A. T. Dren, G. D. Rudd, and C. G. Lineberry. “Placebo-controlled study of the efficacy and safety of lamotrigine in patients with partial seizures. U.S. Lamotrigine Protocol 0.5 Clinical Trial Group.” Neurology 43, no. 11 (November 1993): 2284–91. https://doi.org/10.1212/wnl.43.11.2284.Full Text Link to Item
-
Dren, A. T., M. E. Risner, G. P. Womble, M. K. Yau, G. D. Rudd, and C. G. Lineberry. “Placebo-controlled add-on experience demonstrating the safety and efficacy of lamotrigine in patients with refractory partial seizures.” Journal of Clinical Pharmacology 32 (1992): 766.
-
Rudd, G. D., A. T. Dren, G. P. Womble, M. E. Risner, and C. G. Lineberry. “Comparison of crossover and parallel designs in the clinical evaluation of lamotrigine.” Pharmacotherapy 12 (1992): 263.
-
Borison, R. L., B. I. Diamond, and A. T. Dren. “Does sigma receptor antagonism predict clinical antipsychotic efficacy?” Psychopharmacology Bulletin 27, no. 2 (January 1991): 103–6.
-
DREN, A. T., D. M. EBERT, E. J. WARAWA, and P. W. DODGE. “INTRAVENOUS ANESTHETIC ACTIVITY OF BICYCLIC KETALS STRUCTURALLY RELATED TO KETAMINE AND ETOXADROL.” Pharmacology Biochemistry and Behavior 28, no. 1 (September 1, 1987): 122–122.Link to Item
-
Dren, A. T., C. W. Gorodetzky, and A. Cato. “Case report: The case of the disappearing white blood cells.” J Clin Res Drug Dev 1 (1987): 79–86.
-
WHITE, H. L., and A. T. DREN. “SOME PRECLINICAL AND CLINICAL PHARMACOLOGICAL PROPERTIES OF BW-A616U, A REVERSIBLE MAO-A INHIBITOR.” Clinical Neuropharmacology 9 (January 1, 1986): 561–62.Link to Item
-
Davidson, J., A. Dren, R. Miller, P. Manberg, C. Kilts, and M. Wingfield. “BW234U: a non-dopamine receptor blocking antipsychotic drug without extrapyramidal effects?” Drug Development Research 6, no. 1 (1985): 13–17.
-
Warawa, E., A. T. Dren, and D. M. Ebert. “Synthesis and intravenous general anesthetic activity of 7-aza-II, 12-dioxxa-6-phenuyltricyclo-7,2,1,0 dodecanes.” Journal of Medicinal Chemistry 28 (1985).
-
Schwarcz, G., A. Halaris, A. Dren, and P. Manberg. “Open-label evaluation of the novel antipsychotic compound BW234U in chronic schizophrenics.” Drug Development Research 5, no. 4 (1985): 387–93. https://doi.org/10.1002/ddr.430050412.Full Text
-
Feighner, J. P., A. T. Dren, and P. J. Manberg. “Clinical experience with a new antipsychotic without dopamine blocking properties.” Clin Neuropharmacol 7, no. Suppl 1 (1984): 148–49.
-
Lee, C. M., H. E. Zaugg, R. J. Michaels, A. T. Dren, N. P. Plotnikoff, and P. R. Young. “New azacannabinoids highly active in the central nervous system.” Journal of Medicinal Chemistry 26, no. 2 (February 1983): 278–80. https://doi.org/10.1021/jm00356a031.Full Text
-
Guy, W., G. Manov, W. H. Wilson, T. A. Ban, O. K. Fjetland, P. J. Manberg, and A. T. Dren. “Psychotropic actions of BW 234U in the treatment of inpatient schizophrenics: A dose‐range study.” Drug Development Research 3, no. 3 (January 1, 1983): 245–52. https://doi.org/10.1002/ddr.430030306.Full Text
-
Davidson, J., R. Miller, M. Wingfield, W. Zung, and A. T. Dren. “The first clinical study of BW-234U in schizophrenia.” Psychopharmacol Bull 18, no. 4 (October 1982): 173–76.Link to Item
-
Minard, F. N., J. C. Cain, D. S. Grant, and A. T. Dren. “N-o-Methoxyphenylpiperazine: a simple blocker of dopaminergic receptors in the brain.” The Journal of Pharmacy and Pharmacology 31, no. 2 (February 1979): 91–93. https://doi.org/10.1111/j.2042-7158.1979.tb13439.x.Full Text
-
Bopp, B. A., A. T. Dren, D. M. Ebert, and A. O. Geiszler. “Local anesthetic activity and acute toxicity of N-heptyl-1,2,3,4-tetrahydro-6-methoxy-1-naphthylamine methanesulfonate.” Journal of Pharmaceutical Sciences 67, no. 6 (June 1978): 882–84. https://doi.org/10.1002/jps.2600670648.Full Text
-
Dren, A. T., B. A. Bopp, D. M. Ebert, A. O. Geiszler, J. B. Holland, B. W. Horrom, and D. A. Dunnigan. “Local anesthetic activity and acute toxicity of N-substituted 1,2,3,4-tetrahydro-1- and 2-naphthylamines.” Journal of Pharmaceutical Sciences 67, no. 6 (June 1978): 880–82. https://doi.org/10.1002/jps.2600670647.Full Text
-
Lee, C. M., R. J. Michaels, H. E. Zaugg, A. T. Dren, N. P. Plotnikoff, and P. R. Young. “Cannabinoids. Synthesis and central nervous system activity of 8-substituted 10-hydroxy-5,5-dimethyl-5H-[1]benzopyrano[4,3-c]pyridine and derivatives.” Journal of Medicinal Chemistry 20, no. 11 (November 1977): 1508–11. https://doi.org/10.1021/jm00221a031.Full Text
-
Kirkpatrick, W. E., T. Okabe, I. W. Hillyard, R. K. Robins, A. T. Dren, and T. Novinson. “3-Halo-5,7-dimethylpyrazolo [1,5-a]pyrimidines, a nonbenzodiazepinoid class of antianxiety agents devoid of potentiation of central nervous system depressant effects of ethanol or barbiturates.” Journal of Medicinal Chemistry 20, no. 3 (March 1977): 386–93. https://doi.org/10.1021/jm00213a014.Full Text
-
Razdan, R. K., B. Z. Terris, H. G. Pars, N. P. Plotnikoff, P. W. Dodge, A. T. Dren, J. Kyncl, and P. Somani. “Drugs derived from cannabinoids. 2. Basic esters of nitrogen and carbocyclic analogs.” Journal of Medicinal Chemistry 19, no. 4 (April 1976): 454–61. https://doi.org/10.1021/jm00226a002.Full Text
-
Razdan, R. K., G. R. Handrick, H. C. Dalzell, J. F. Howes, M. Winn, N. P. Plotnikoff, P. W. Dodge, and A. T. Dren. “Drugs derived from cannabinoids. 4. Effect of alkyl substitution in sulfur and carbocyclic analogs.” Journal of Medicinal Chemistry 19, no. 4 (April 1976): 552–54. https://doi.org/10.1021/jm00226a023.Full Text
-
Razdan, R. K., B. Z. Terris, G. R. Handrick, H. C. Dalzell, H. G. Pars, J. F. Howes, N. Plotnikoff, et al. “Drugs derived from cannabinoids. 3. Sulfur analogs, thiopyranobenzopyrans and thienobenzopyrans.” Journal of Medicinal Chemistry 19, no. 4 (April 1976): 549–51. https://doi.org/10.1021/jm00226a022.Full Text
-
Winn, M., D. Arendsen, P. Dodge, A. Dren, D. Dunnigan, R. Hallas, K. Hwang, et al. “Drugs derived from cannabinoids. 5. Delta 6a, 10a-tetrahydrocannabinol and heterocyclic analogs containing aromatic side chains.” Journal of Medicinal Chemistry 19, no. 4 (April 1976): 461–71.
-
Dren, A. T., and E. F. Domino. “Cholinergic and adrenergic activating agents as antagonists of the EEG effects of hemicholinium-3.” Archives Internationales De Pharmacodynamie Et De Therapie 175, no. 1 (September 1968): 63–72.
-
Dren, A. T., and E. F. Domino. “Effects of hemicholinium (HC-3) on EEG activation and brain acetylcholine in the dog.” The Journal of Pharmacology and Experimental Therapeutics 161, no. 1 (May 1968): 141–54.
-
Rosecrans, J. A., A. T. Dren, and E. F. Domino. “Effects of physostigmine on rat brain acetylcholine, acetylcholinesterase and conditioned pole jumping.” International Journal of Neuropharmacology 7, no. 2 (March 1968): 127–34. https://doi.org/10.1016/0028-3908(68)90006-3.Full Text
-
Domino, E. F., K. Yamamoto, and A. T. Dren. “Role of cholinergic mechanisms in states of wakefulness and sleep.” Progress in Brain Research 28 (January 1968): 113–33. https://doi.org/10.1016/s0079-6123(08)64547-1.Full Text
-
Dren, A. T. “EEG Evaluation of Drug Action.” Intek 4 (1968): 1–3.
-
Domino, E. F., A. T. Dren, and K. I. Yamamoto. “Pharmacologic evidence for cholinergic mechanisms in neocortical and limbic activating systems.” Progress in Brain Research 27 (January 1967): 337–64. https://doi.org/10.1016/s0079-6123(08)63109-x.Full Text
-
-
- Teaching & Mentoring
-
Recent Courses
Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.